Patricia Ganz named editor in chief of Journal of the National Cancer Institute

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Patricia Ganz will replace Carmen Allegra as editor-in-chief of JNCI.

This move was precipitated by Allegra’s recent assignment at NCI as the head of gastrointestinal therapeutics of the Clinical Investigations Branch at the Cancer Therapy Evaluation Program. Allegra will continue at JNCI as deputy editor.

Ganz is a professor of health policy and management in the Fielding School of Public Health, and a professor of medicine in the David Geffen School of Medicine at UCLA. She also serves as director of Cancer Prevention & Control Research at UCLA’s Jonsson Comprehensive Cancer Center.

As editor-in-chief, Ganz is responsible for JNCI Monographs, a supplement publication that provides a venue for conference proceedings or topic areas where a series of related articles serve a scientific purpose.

During the past two years, JNCI has developed a series of virtual collections curated from prior publications; these thematically organized collections focus on timely selected topics and are featured online with free access for several months.

YOU MAY BE INTERESTED IN

Recently, HHS Secretary Robert F. Kennedy Jr. posted a video montage featuring himself shirtless in jeans, working out with Kid Rock. The duo is in a blue-lit grotto with a cold plunge and sauna. Set to Kid Rock’s “Bawitdaba” and intercut with a selection of patriotic imagery, the video ends with the two men in a hot tub, chugging what appears to be milk.
In January, FDA released a draft guidance entitled “Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints to Support Accelerated Approval.” This release came roughly 20 months after the Oncologic Drugs Advisory Committee (ODAC) voted unanimously that minimal residual disease (MRD) negativity, in combination with complete response (CR), is an acceptable primary endpoint to support accelerated approval for multiple myeloma (MM) therapies. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login